The Crosstalk Between Bone Remodeling and Energy Metabolism: A Translational Perspective

Overview

Journal Cell Metab

Publisher Cell Press

Specialties Cell Biology
Endocrinology

Date 2022 May 11

PMID 35545088

Authors

Gerard Karsenty

Sundeep Khosla

Affiliations

Soon will be listed here.

Abstract

Genetics in model organisms has progressively broken down walls that previously separated different disciplines of biology. One example of this holistic evolution is the recognition of the complex relationship that exists between the control of bone mass (bone remodeling) and energy metabolism in mammals. Numerous hormones orchestrate this crosstalk. In particular, the study of the leptin-mediated regulation of bone mass has not only revealed the existence of a central control of bone mass but has also led to the realization that sympathetic innervation is a major regulator of bone remodeling. This happened at a time when the use of drugs aiming at treating osteoporosis, the most frequent bone disease, has dwindled. This review will highlight the main aspects of the leptin-mediated regulation of bone mass and how this led to the realization that β-blockers, which block the effects of the sympathetic nervous system, may be a viable option to prevent osteoporosis.

Citing Articles

Repair mechanisms of bone system tissues based on comprehensive perspective of multi-omics.

Yu H, Yang S, Jiang T, Li T, Duan H, Li M Cell Biol Toxicol. 2025; 41(1):45.

PMID: 39966216 PMC: 11836151. DOI: 10.1007/s10565-025-09995-5.

Targeted inhibition of ferroptosis in bone marrow mesenchymal stem cells by engineered exosomes alleviates bone loss in smoking-related osteoporosis.

Wang Y, Sun L, Dong Z, Zhang T, Wang L, Cao Y Mater Today Bio. 2025; 31:101501.

PMID: 39944529 PMC: 11815285. DOI: 10.1016/j.mtbio.2025.101501.

The RGD region of bone sialoprotein affects metabolic activity in mice.

Nagasaki K, Nagasaki A, Taylor J, Kear B, Ma Y, Somerman M Front Dent Med. 2025; 4:1124084.

PMID: 39916931 PMC: 11797800. DOI: 10.3389/fdmed.2023.1124084.

Degradation products of magnesium implant synergistically enhance bone regeneration: Unraveling the roles of hydrogen gas and alkaline environment.

An Y, Zhang H, Zhang S, Zhang Y, Zheng L, Chen X Bioact Mater. 2025; 46():331-346.

PMID: 39816475 PMC: 11732853. DOI: 10.1016/j.bioactmat.2024.12.020.

Impact of dementia and mild cognitive impairment on bone health in older people.

Curtis E, Miguel M, McEvoy C, Ticinesi A, Torre C, Al-Daghri N Aging Clin Exp Res. 2024; 37(1):5.

PMID: 39725855 PMC: 11671436. DOI: 10.1007/s40520-024-02871-y.

References

Cosman F, de Beur S, LeBoff M, Lewiecki E, Tanner B, Randall S . Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10):2359-81. PMC: 4176573. DOI: 10.1007/s00198-014-2794-2. View

Karsenty G, Ferron M . The contribution of bone to whole-organism physiology. Nature. 2012; 481(7381):314-20. PMC: 9047059. DOI: 10.1038/nature10763. View

Khrimian L, Obri A, Ramos-Brossier M, Rousseaud A, Moriceau S, Nicot A . Gpr158 mediates osteocalcin's regulation of cognition. J Exp Med. 2017; 214(10):2859-2873. PMC: 5626410. DOI: 10.1084/jem.20171320. View

Iepsen E, Lundgren J, Hartmann B, Pedersen O, Hansen T, Jorgensen N . GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. J Clin Endocrinol Metab. 2015; 100(8):2909-17. DOI: 10.1210/jc.2015-1176. View

Yadav V, Oury F, Suda N, Liu Z, Gao X, Confavreux C . A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell. 2009; 138(5):976-89. PMC: 2768582. DOI: 10.1016/j.cell.2009.06.051. View

Bruning J, Michael M, Winnay J, Hayashi T, Horsch D, Accili D . A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell. 1998; 2(5):559-69. DOI: 10.1016/s1097-2765(00)80155-0. View

Kajimura D, Lee H, Riley K, Arteaga-Solis E, Ferron M, Zhou B . Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab. 2013; 17(6):901-915. PMC: 3679303. DOI: 10.1016/j.cmet.2013.04.009. View

Cauley J, Wampler N, BARNHART J, Wu L, Allison M, Chen Z . Incidence of fractures compared to cardiovascular disease and breast cancer: the Women's Health Initiative Observational Study. Osteoporos Int. 2008; 19(12):1717-23. PMC: 2663802. DOI: 10.1007/s00198-008-0634-y. View

Ducy P, Zhang R, Geoffroy V, Ridall A, Karsenty G . Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997; 89(5):747-54. DOI: 10.1016/s0092-8674(00)80257-3. View

10.

Zhong Q, Itokawa T, Sridhar S, Ding K, Xie D, Kang B . Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab. 2006; 292(2):E543-8. DOI: 10.1152/ajpendo.00364.2006. View

11.

Kim S, Kim D, Mogun H, Eddings W, Polinski J, Franklin J . Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture. J Bone Miner Res. 2016; 31(8):1536-40. PMC: 5040596. DOI: 10.1002/jbmr.2832. View

12.

Nuttall S, Routledge H, Kendall M . A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther. 2003; 28(3):179-86. DOI: 10.1046/j.1365-2710.2003.00477.x. View

13.

Zou W, Rohatgi N, Brestoff J, Zhang Y, Scheller E, Craft C . Congenital lipodystrophy induces severe osteosclerosis. PLoS Genet. 2019; 15(6):e1008244. PMC: 6611650. DOI: 10.1371/journal.pgen.1008244. View

14.

Toulis K, Hemming K, Stergianos S, Nirantharakumar K, Bilezikian J . β-Adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects. Osteoporos Int. 2013; 25(1):121-9. DOI: 10.1007/s00198-013-2498-z. View

15.

Xie D, Cheng H, Hamrick M, Zhong Q, Ding K, Correa D . Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone. 2005; 37(6):759-69. DOI: 10.1016/j.bone.2005.06.021. View

16.

Ganz T . Hepcidin and iron regulation, 10 years later. Blood. 2011; 117(17):4425-33. PMC: 3099567. DOI: 10.1182/blood-2011-01-258467. View

17.

Ortuno M, Robinson S, Subramanyam P, Paone R, Huang Y, Guo X . Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect. Nat Med. 2016; 22(10):1170-1179. PMC: 5053870. DOI: 10.1038/nm.4166. View

18.

Khosla S, Hofbauer L . Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017; 5(11):898-907. PMC: 5798872. DOI: 10.1016/S2213-8587(17)30188-2. View

19.

Sato S, Hanada R, Kimura A, Abe T, Matsumoto T, Iwasaki M . Central control of bone remodeling by neuromedin U. Nat Med. 2007; 13(10):1234-40. DOI: 10.1038/nm1640. View

20.

Mercado-Asis L, Wolf K, Jochmanova I, Taieb D . PHEOCHROMOCYTOMA: A GENETIC AND DIAGNOSTIC UPDATE. Endocr Pract. 2017; 24(1):78-90. DOI: 10.4158/EP-2017-0057. View